Funding

California-Based System Raises $20M in New Funding

Sep 10, 2026 | By Devin Jacobs

SUMMARY

System raised $20M in new funding.
Funds will support expansion and peptide infrastructure.
System is a peptide healthcare platform.

System, a San Francisco, CA-based provider of a peptide platform connecting patients with clinicians and pharmacy-grade compound treatments, has raised $20 million in a new funding round.

The round saw backers Patron Fund, Will Ventures, Vine, Courtside, Daybreak, SV Angel, and RiverPark Ventures.

The company will use the capital to accelerate expansion and build the infrastructure needed for its peptide supply chain.

Funding Snapshot

Metric	Details
Fundraise Amount	$20 million
Funding Round	New Funding
Company	System
Sector	Health & Wellness / Peptide Treatments
Headquarters	San Francisco, California
Key Focus	Physician-guided peptide treatments

RECOMMENDED FOR YOU

Funding

[Funding alert] ProHance Secures Majority Investment from ChrysCapital

Devin Jacobs

Dec 9, 2023

Funding

Data Analytics-Based Ours Privacy Raises $15M in Series A Funding

Devin Jacobs

Aug 20, 2026

Funding

[Funding alert] NYC-based Rally Secures $8.8Million in Seed Funding

Devin Jacobs

Apr 10, 2024

About System

Founded by Adam Steinle, System is a vertically integrated peptide platform that connects patients with US licensed clinicians and certified American compounding pharmacies.

Patients are evaluated by clinicians who prescribe personalized peptide protocols. The treatments are then compounded by pharmacies and shipped directly to patients.

Core offerings include:

Physician-guided peptide treatments
Personalized peptide protocols
Third-party lab-tested products
Pharmacy compounded treatments

Core Technologies / Products / Services

Capability/Product	Application/Use Case
Clinical platform	Connects patients with licensed U.S. clinicians
Personalized protocols	Provides peptide treatments based on individual health history
Compounding pharmacy network	Supports preparation and fulfillment of treatments
Supply chain infrastructure	Provides greater control and transparency over peptide products

Leadership Comments

"My vision was never to be another DTC telehealth brand, but to own more of the stack, and build the foundation this category needs as it moves into the mainstream," says Adam Steinle, Founder and CEO of System. "We want to be category definers and the solution Americans use, and trust for their long term health.

"Peptides are moving from the edges of wellness into mainstream consumer culture. As healthcare becomes more personal, and increasingly part of how people express their identity, the category-defining companies will be built by founders who understand that trust, quality and brand are inseparable. Adam understood this consumer shift better than anyone. System is building the trusted consumer company that can define this category," says Amber Atherton, Partner at Patron.